CNBX Pharmaceuticals Inc. (CNBX) Net Margin (2016 - 2024)

CNBX Pharmaceuticals' (CNBX) quarterly Net Margin came in at 521.14% in Q1 2024, down 154.21% on a QoQ basis from 205.01% in Q4 2023.

CNBX Pharmaceuticals Inc. (CNBX) Net Margin (2016 - 2024) Analysis & Trends

CNBX Pharmaceuticals (CNBX) has 8 years of Net Margin data on file, last reported at 521.14% in Q1 2024.

Quarterly Net Margin changed N/A year-over-year to 521.14% in Q1 2024, while the trailing twelve-month figure through Nov 2024 was 1139.04% (down 98600.0% YoY) and the FY2024 annual result came in at 3113.42%, down 207259.0% from the prior year.
Net Margin eased to 521.14% in Q1 2024, from 205.01% in the prior quarter.
In the past five years, Net Margin ranged from a high of 52.89% in Q2 2023 to a low of 194220.98% in Q3 2020.
A 4-year average of 37444.28% and a median of 1082.56% in 2022 frame the typical range for Net Margin.
Annual changes were most pronounced in 2020 — Net Margin plunged 4968303 bps — and 2023, when it surged 148132 bps.
Tracing CNBX's Net Margin over 4 years: stood at 194220.98% in 2020, then jumped by 99 bps to 1643.99% in 2022, then jumped by 88 bps to 205.01% in 2023, then sank by 154 bps to 521.14% in 2024.
The last three Net Margin figures came in at 521.14% (Q1 2024), 205.01% (Q4 2023), and 162.67% (Q3 2023), per Business Quant data.

Download Data